Impedimed (ASX:IPD) Ending Cash Position: A$18.85 Mil (As of Dec. 2025)


What is Impedimed Ending Cash Position?

Impedimed ASX:IPD -8.33% Ending Cash Position is A$18.85 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Impedimed's Ending Cash Position for the quarter that ended in Dec. 2025 was A$18.85 Mil.

Impedimed's quarterly Ending Cash Position increased from Dec. 2024 (A$17.69 Mil) to Jun. 2025 (A$22.18 Mil) but then declined from Jun. 2025 (A$22.18 Mil) to Dec. 2025 (A$18.85 Mil).

Impedimed's annual Ending Cash Position declined from Jun. 2023 (A$45.71 Mil) to Jun. 2024 (A$24.63 Mil) and declined from Jun. 2024 (A$24.63 Mil) to Jun. 2025 (A$22.18 Mil).

Impedimed Ending Cash Position Related Terms

Impedimed Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Impedimed's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Impedimed Ending Cash Position Chart

Impedimed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.68 40.73 45.71 24.63 22.18

Impedimed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.91 24.63 17.69 22.18 18.85

Impedimed Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Impedimed's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=24.632+-2.449
=22.18

Impedimed's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=22.183+-3.336
=18.85

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$18.85 Mil mean?
Impedimed (ASX:IPD) has a Ending Cash Position of A$18.85 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Impedimed and its competitors.
Is Impedimed's Ending Cash Position too high?
Impedimed's current Ending Cash Position is A$18.85 Mil.
How does Impedimed's Ending Cash Position compare to ABT and SYK?
Impedimed's Ending Cash Position of A$18.85 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Impedimed and its competitors. Impedimed's current Ending Cash Position is A$18.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.08, compared to a current price of A$0.01 — trading 93.1% below its estimated fair value. The current Ending Cash Position is A$18.85 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current Ending Cash Position is A$18.85 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Impedimed Business Description

Other Exchanges IPDQF:USA
Address 5900 Pasteur Court, Suite 125, Carlsbad, CA, USA, 92008
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.